Dr. Albiges on Next Steps for Immunotherapy in RCC

Laurence Albiges, MD
Published: Friday, Aug 18, 2017



Laurence Albiges, MD, ‎medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses the next steps for immunotherapy for patients with renal cell carcinoma (RCC).

There is now access to nivolumab (Opdivo) in most countries due to its efficacy in overall survival compared with everolimus (Afinitor) and its safety profile, explains Albiges.

However, given the risks that still exist, more needs to be done to continue to develop the treatment landscape, states Albiges. Physicians are now investigating combination strategies that might improve outcomes.
 


Laurence Albiges, MD, ‎medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses the next steps for immunotherapy for patients with renal cell carcinoma (RCC).

There is now access to nivolumab (Opdivo) in most countries due to its efficacy in overall survival compared with everolimus (Afinitor) and its safety profile, explains Albiges.

However, given the risks that still exist, more needs to be done to continue to develop the treatment landscape, states Albiges. Physicians are now investigating combination strategies that might improve outcomes.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x